Table 3.
Subsequent therapy by tumor PD-L1 expression in Japanese patients with a PFS event per BICR and in patients alive at 5 years (PD-L1 ≥ 1% and < 1%)
| Patients with a PFS event, n (%) | PD-L1 ≥ 1% | PD-L1 < 1% | PD-L1 ≥ 1% and < 1% | |||
|---|---|---|---|---|---|---|
| Nivolumab plus ipilimumab (n = 26) |
Chemotherapy (n = 33) |
Nivolumab plus ipilimumab (n = 19) |
Chemotherapy (n = 19) |
Nivolumab plus ipilimumab (n = 45) |
Chemotherapy (n = 52) |
|
| Any | 19 (73) | 29 (88) | 16 (84) | 17 (89) | 35 (78) | 46 (88) |
| Radiotherapy | 11 (42) | 12 (36) | 8 (42) | 7 (37) | 19 (42) | 19 (37) |
| Surgery | 1 (4) | 1 (3) | 1 (5) | 0 | 2 (4) | 1 (2) |
| Systemic therapy | 15 (58) | 28 (85) | 15 (79) | 16 (84) | 30 (67) | 44 (85) |
| Chemotherapy | 14 (54) | 20 (61) | 15 (79) | 10 (53) | 29 (64) | 30 (58) |
| Immunotherapy | 4 (15) | 27 (82) | 4 (21) | 15 (79) | 8 (18) | 42 (81) |
| PD-1 inhibitors | 4 (15) | 26 (79) | 2 (11) | 14 (74) | 6 (13) | 40 (77) |
| Nivolumab | 2 (8) | 22 (67) | 1 (5) | 12 (63) | 3 (7) | 34 (65) |
| PDR001 | 0 | 1 (3) | 0 | 0 | 0 | 1 (2) |
| Pembrolizumab | 2 (8) | 5 (15) | 1 (5) | 2 (11) | 3 (7) | 7 (13) |
| PD-L1 inhibitors | 1 (4) | 3 (9) | 3 (16) | 1 (5) | 4 (9) | 4 (8) |
| Atezolizumab | 0 | 3 (9) | 2 (11) | 1 (5) | 2 (4) | 4 (8) |
| Durvalumab | 1 (4) | 0 | 1 (5) | 0 | 2 (4) | 0 |
| Targeted therapy | 4 (15) | 9 (27) | 6 (32) | 7 (37) | 10 (22) | 16 (31) |
| Experimental drugs | 1 (4) | 2 (6) | 1 (5) | 2 (11) | 2 (4) | 4 (8) |
| 5-year survivors, n (%) | PD-L1 ≥ 1% and < 1% | |
|---|---|---|
| Nivolumab plus ipilimumab (n = 27) |
Chemotherapy (n = 20) |
|
| Any | 13 (48) | 18 (90) |
| Radiotherapy | 7 (26) | 4 (20) |
| Surgery | 3 (11) | 1 (5) |
| Systemic therapy | 11 (41) | 17 (85) |
| Chemotherapy | 10 (37) | 8 (40) |
| Immunotherapy | 4 (15) | 17 (85) |
| PD-1 inhibitors | 2 (7) | 15 (75) |
| Nivolumab | 0 | 12 (60) |
| Pembrolizumab | 2 (7) | 3 (15) |
| PD-L1 inhibitors | 3 (11) | 3 (15) |
| Atezolizumab | 2 (7) | 3 (15) |
| Durvalumab | 1 (4) | 0 |
| Targeted therapy | 7 (26) | 4 (20) |
| Experimental drugs | 1 (4) | 4 (20) |
Percentages may not sum to 100% as patients may have received more than 1 type of subsequent therapy (defined as therapy started on or after first dosing date [or randomization date if the patient had not received study treatment])
BICR blinded independent review; PD-1 programmed death-1; PD-L1 programmed death ligand 1; PFS progression-free survival